This was tons of fun. IMO, Matthew Pillar is the best podcast host in biotech. lnkd.in/gXZhFj85

I wish I were as good as Brian Buntz at distilling complex science into a simple story. The piece he published yesterday on our LMN-201 product captures the full story in just 750 words, including a fair amount of technical detail. Impressive!

Join us next Tuesday as our CEO Brian Finrow moderates Life Science Washington's expert panel on moving new drugs into the clinic. March 25, 2025 | 11:30 AM - 1:30 PM | Seattle, WA Register through Life Science WA: lifesciencewa.org/events

Breaking through intranasal biologics production barriers. Our CEO Brian Finrow presents "Keep It Simple Stupid" at the Hanson Wade Nasal Formulation Summit in Boston next week. Register: nasal-formulation-delivery.com April 1-3, 2024 | Boston, MA

Promising news for C. diff patients! 100% of patients with LMN-201 + antibiotics successfully resolved their primary infection, and 95% of participants had no recurrence within 28 days (RePreve Trial sentinel cohort results). shorturl.at/30HaG #PatientCare #Clinicaltrial

Good or bad, when institutions are remade it's an opportunity for fresh new ideas to root. There's plenty of negative criticism out there—from all sides—but Sandeep Patel and I jotted down some constructive ideas to throw into the mix—published here in STAT

.Ross Rheingans-Yoo🔸 doesn't ask easy questions—he asks the right ones. Honored to be an early guest on the new Development & Research interview series, where we dug deep on what makes drug development tick.

Excited to announce Erik Anderson as Vice Chairman of our Board. As CEO of WestRiver Group & Singularity, Erik led our Series C and brings invaluable experience as we scale our spirulina-based biologics platform. lumen.bio/news/2025/10/0…

Welcoming Jeff Raikes to our board! His leadership experience at Microsoft, Gates Foundation & Costco will be invaluable as we scale our biologics platform globally. lumen.bio/news/2025/10/0…

Congratulations to Nhi Khuong, PhD on her promotion to Executive Vice President! Her scientific leadership has been crucial in advancing our biologics platform through clinical development as we prepare for LMN-201's launch. lumen.bio/news/2025/10/0…

Proud to announce Kole Krieger's promotion to Senior Vice President! His leadership in partnerships and operational excellence is crucial as we prepare for LMN-201's launch and advance our oral biologics pipeline. lumen.bio/news/2025/10/0…

Thrilled to welcome David Saunders, MD, MPH to our clinical development team! A distinguished U.S. Army Colonel & clinical trialist, his expertise in infectious disease research will be crucial as we advance LMN-201 and our oral biologics pipeline. lumen.bio/news/2025/10/0…

Think slow drug development = safe? Wrong. Australia approves low-risk trials in weeks. COVID proved remote trials work. China's biotech now dominates 1/3 of pharma acquisitions—not better science, just faster regulation. Time to fix U.S. inefficiencies. statnews.com/2025/06/03/us-